Intensity modulated radiotherapy (IMRT) has become widely used as a standard radiation therapy technique for the treatment of localized prostate cancer. The transition from conformal radiotherapy (3D ...CRT) to a more complex IMRT technique triggered the need for more thorough verification of the accuracy in the dose delivery. In this work we present the clinical workflow and the results of patient specific quality assurance (PSQA) procedures for 40 prostate cancer patients who have been treated with step and shot IMRT ever since its implementation in our routine clinical practice. PSQA procedures include dosimetric verification of each treatment plan with dedicated rotational phantom and high-resolution matrix detector system Octavius 4D (PTW Freiburg) that allows three-dimensional comparison of the calculated and delivered radiation dose distribution. Our results proved the compliance with the universal tolerance limits recommended for those procedures (1), assuring the safety of the treatment and providing the possibility for the adoption of more stringent constraints in the future.
Intensity modulated radiotherapy (IMRT) has become widely used as a standard radiation therapy technique for the treatment of localized prostate cancer. The transition from conformal radiotherapy (3D ...CRT) to a more complex IMRT technique triggered the need for more thorough verification of the accuracy in the dose delivery. In this work we present the clinical workflow and the results of patient specific quality assurance (PSQA) procedures for 40 prostate cancer patients who have been treated with step and shot IMRT ever since its implementation in our routine clinical practice. PSQA procedures include dosimetric verification of each treatment plan with dedicated rotational phantom and high-resolution matrix detector system Octavius 4D (PTW Freiburg) that allows three-dimensional comparison of the calculated and delivered radiation dose distribution. Our results proved the compliance with the universal tolerance limits recommended for those procedures (1), assuring the safety of the treatment and providing the possibility for the adoption of more stringent constraints in the future. Key words: prostate IMRT, patient specific QA Radioterapija moduliranog intenziteta (eng intensity modulated radiotherapy -IMRT) u posljednjem desetljecu je postala uobicajena radioterapijska metoda za terapiju lokaliziranih karcinoma prostate. Prelazak s konformalne radioterapije na napredniju i tehnicki slozeniju IMRT tehniku, donio je i potrebu za detaljnijom i sveobuhvatnom provjerom tocnosti isporuke doze zracenja. U ovom radu predstavljamo provodenje postupaka dozimetrijske verifikacije radio terapijskih planova poznatih pod engleskim nazivom patient specific QA (PSQA) te rezultate za 40 bolesnika s karcinomom prostate koji su primili IMRT terapiju. U tu svrhu koristimo posebni dozimetrijski sustav s rotacijskim fantomom i visoko razlucivom detektorskom matricom, Octavius 4D (PTW Freiburg). Pokazalo se kako su sva dobivena odstupanja izmedu planirane i mjerene trodimenzionalne raspodjele doze bila unutar preporucenih tolerancija (1) sto nam daje povjerenje u sigurnost provodenja ovakve terapije te otvara mogucnost za primjenu strozijih ogranicenja u buducnosti. Kljucne rijeci: radioterapija moduliranog intenziteta (IMRT) karcinoma prostate, dozimetrijska verifikacija plana, patient specific QA (PSQA)
Summary
BACKGROUND: Mitral valve prolapse (MVP) is a common diagnosis in patients with primary spontaneous pneumothorax (PSP). This description assumes that MVP and PSP might be manifestations of a ...systemic connective tissue abnormality. The purpose of this study was to determine the prevalence of MVP in PSP patients of Croatian origin and evaluate their relationship with connective tissue disorders. We also examined the prevalence of PSP in patients with primary MVP. METHODS: Thirty-two patients with PSP and without underlying pulmonary disease or connective tissue disease underwent two-dimensional transthoracic echocardiography performed by a certified cardiologist. Echocardiography and demographic features were analyzed using descriptive statistics. We also examined the medical records of 60 patients with primary MVP. RESULTS: MVP was found in none of the 32 patients suffering from PSP. The age, sex, smoking status, body mass index, side, rate, and family history were similar to previous investigations. Likewise, none of the 60 patients with primary MVP ever had PSP. CONCLUSION: By applying an updated definition of MVP, we found no MVP case among PSP patients of Croatian origin. We also found no PSP in the primary MVP group. Ethnicity may influence the occurrence of MVP in PSP patients, and PSP in primary MVP patients.
Full text
Available for:
EMUNI, FIS, FZAB, GEOZS, GIS, IJS, IMTLJ, KILJ, KISLJ, MFDPS, NLZOH, NUK, OILJ, PNG, SAZU, SBCE, SBJE, SBMB, SBNM, UKNU, UL, UM, UPUK, VKSCE, ZAGLJ
